Preclinical models of osteosarcoma have demonstrated that LAG-3 blockade, when combined with PD-1 inhibition, results in increased tumor regression in murine models, further supporting the therapeutic potential of targeting LAG-3 in osteosarcoma. Here, PDCD1 is linked to neoplasm.